Annovis Bio Stock Among Retail's Top Draws After FDA Nod For Final Phase 3 Alzheimer’s Study Protocol

Barchart · 01/07 09:20
According to CEO Maria Maccecchini, the new streamlined design potentially enables a New Drug Application filing based on the six-month data.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.